CPA Releases New Economics Report on America’s Chip-for-Chip Tariff Policy

CPA Releases New Economics Report on America’s Chip-for-Chip Tariff Policy

The report, titled “America’s Chip-for-Chip Tariff Policy: The Urgent Fight to Reclaim Industrial Independence Before It’s Too Late,” finds that the United States now produces only 10 percent of the world’s chips—and almost none of the most advanced ones—while China has captured the majority of global capacity for legacy chips, the mature semiconductors essential to cars, medical devices, and industrial equipment.

CPA’s Jeff Ferry Teaches the Next Generation How to Rebuild American Industry

CPA’s Jeff Ferry Teaches the Next Generation How to Rebuild American Industry

CPA’s chief economist emeritus, Jeff Ferry, has gone back to school in his semi-retirement years. This time, though, it was a speaking gig at the University of Florida’s new Semiconductor Institute in Gainesville.

CPA Economist Leads Rare Bipartisan Push to Fix America’s Generic Drug Crisis

CPA Economist Leads Rare Bipartisan Push to Fix America’s Generic Drug Crisis

CPA Economist Andrew Rechenberg gave his testimony and answered questions in a four- panelist hearing. It was arguably the most agreeable hearing in years. A bipartisan consensus on America’s generic drug supply chain is nearly fully formed now.

Pharmaceutical 232 Must Cover Generic Drugs to Fulfill President’s Promise of Reshoring Essential Medicine Production

Pharmaceutical 232 Must Cover Generic Drugs to Fulfill President’s Promise of Reshoring Essential Medicine Production

The Trump administration’s Section 232 investigation into pharmaceutical imports is reportedly close to being final. The final investigation’s success will depend largely on whether or not the Commerce Department determines that there is a crisis in the generics industry — an issue that President Trump highlighted back in 2023.